Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Is Novo Nordisk Stock a Bargain Right Now?
01:48pm, Monday, 02'nd Feb 2026
Novo Nordisk was a leader in GLP-1 weight loss but was displaced by Eli Lilly. Investors have punished Novo Nordisk's stock, with the shares having lost more than half their value since mid-2024.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
11:25am, Monday, 02'nd Feb 2026
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients
11:05am, Monday, 02'nd Feb 2026
Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema reduced blood sugar levels and body weight more than semaglutide alone in a late-stage trial of patients with ty
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1. CagriSema achieved superior HbA1c reductio
Obesity market sales potential tightens as Novo and Lilly enter new era
06:07am, Monday, 02'nd Feb 2026
The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments f
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?
06:45am, Saturday, 31'st Jan 2026
In December, it earned approval for the oral version of its famous medicine. Novo Nordisk's newest product launch is proving very popular.
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
06:24pm, Friday, 30'th Jan 2026
Novo Nordisk obtained approval for its GLP-1 weight loss pill late last year. The company has already launched the drug, and there were more than 18,000 prescriptions in the U.S. in just its first wee
Novo Jumps Ahead as Wegovy Pill Takes Off
01:59pm, Friday, 30'th Jan 2026
Novo Nordisk (NVO) is finally getting some momentum back, and the early response to its Wegovy pill is doing the heavy lifting. Fresh prescription data suggest
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
11:11am, Friday, 30'th Jan 2026
NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.
Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
11:09am, Friday, 30'th Jan 2026
Novo Nordisk A/S has first-mover advantage in obesity pills and aggressive U.S. marketing, supported by a robust cash position, strengthen its competitive stance in the thriving GLP-1 market. Consensu
Novo Nordisk Shares Jump 14% as Wegovy Pill Launch Lifts Sentiment
10:57am, Friday, 30'th Jan 2026
Novo Nordisk A/S (NVO) shares have started the year with a sharp rebound after suffering their worst year on record, with the stock up about 14% so far in Janua
New play in Denmark charts Novo Nordisk's weight loss boom
09:18am, Friday, 30'th Jan 2026
A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will premiere on Saturday at a theatre outside Copenhagen.
Novo's Wegovy pill tracks over 26,000 prescriptions
07:30am, Friday, 30'th Jan 2026
Novo Nordisk's Wegovy pill hits over 26,000 U.S. prescriptions in the second full week after its launch, IQVIA data shared by an analyst on Friday showed.
Novo Nordisk's China President Zhou to step down in March
03:48am, Friday, 30'th Jan 2026
Danish pharmaceutical company Novo Nordisk said on Friday that Senior Vice President and head of its business in China Christine Zhou will leave the company at the end of March.
Novo Nordisk: Investors May Be In For An Earnings Surprise
12:39pm, Wednesday, 28'th Jan 2026
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such
